Microglial Endocannabinoid Signalling in AD
暂无分享,去创建一个
M. Maccarrone | V. Carnicelli | A. R. Lizzi | S. Oddi | A. Leuti | L. Scipioni | Francesca Ciaramellano | Noemi De Dominicis
[1] Yafu Yin,et al. Microglia Polarization From M1 to M2 in Neurodegenerative Diseases , 2022, Frontiers in Aging Neuroscience.
[2] E. Denovan‐Wright,et al. The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation , 2022, Frontiers in Pharmacology.
[3] Hongzhuan Chen,et al. TRPV1-Mediated Microglial Autophagy Attenuates Alzheimer’s Disease-Associated Pathology and Cognitive Decline , 2022, Frontiers in Pharmacology.
[4] B. Peng,et al. TRPV1 channel mediates NLRP3 inflammasome-dependent neuroinflammation in microglia , 2021, Cell Death & Disease.
[5] Chu Chen,et al. Endocannabinoid Metabolism and Traumatic Brain Injury , 2021, Cells.
[6] M. Tremblay,et al. Microglial Cannabinoid Type 1 Receptor Regulates Brain Inflammation in a Sex-Specific Manner. , 2021, Cannabis and cannabinoid research.
[7] B. Cravatt,et al. Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer's disease , 2021, Journal of neuroinflammation.
[8] B. Xiao,et al. Microglial Phenotypic Transition: Signaling Pathways and Influencing Modulators Involved in Regulation in Central Nervous System Diseases , 2021, Frontiers in Cellular Neuroscience.
[9] T. Bisogno,et al. Fatty Acid Amide Hydrolase (FAAH) Inhibition Modulates Amyloid-Beta-Induced Microglia Polarization , 2021, International journal of molecular sciences.
[10] Wei Zhou,et al. TRPV1 sustains microglial metabolic reprogramming in Alzheimer's disease , 2021, EMBO reports.
[11] V. Chiurchiù,et al. Specialized Pro-resolving Lipid Mediators and Glial Cells: Emerging Candidates for Brain Homeostasis and Repair , 2021, Frontiers in Cellular Neuroscience.
[12] Samuel S. Duffy,et al. The cannabinoid system and microglia in health and disease , 2021, Neuropharmacology.
[13] S. Haj-Dahmane,et al. Mechanisms of endocannabinoid transport in the brain , 2021, British journal of pharmacology.
[14] D. Mari,et al. Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer’s Disease Patients , 2021, Biomolecules.
[15] E. Brennan,et al. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential. , 2021, European journal of medicinal chemistry.
[16] P. Edison,et al. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? , 2020, Nature Reviews Neurology.
[17] M. Hinescu,et al. CD36 in Alzheimer’s Disease: An Overview of Molecular Mechanisms and Therapeutic Targeting , 2020, Neuroscience.
[18] K. Kuter,et al. Overview of General and Discriminating Markers of Differential Microglia Phenotypes , 2020, Frontiers in Cellular Neuroscience.
[19] M. Maccarrone,et al. Bioactive lipids, inflammation and chronic diseases. , 2020, Advanced drug delivery reviews.
[20] Yi-Hui Deng,et al. Modulators of microglia activation and polarization in ischemic stroke , 2020, Molecular medicine reports.
[21] Yumin Zhang,et al. Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology , 2020, Frontiers in Neurology.
[22] T. Bisogno,et al. Cannabinoids and the expanded endocannabinoid system in neurological disorders , 2019, Nature Reviews Neurology.
[23] Kei Yamamoto,et al. Intracellular Ca2+-dependent formation of N-acyl-phosphatidylethanolamines by human cytosolic phospholipase A2ε. , 2019, Biochimica et biophysica acta. Molecular and cell biology of lipids.
[24] L. Buée,et al. NLRP3 inflammasome activation drives tau pathology , 2019, Nature.
[25] Jun Chen,et al. STAT6/Arg1 promotes microglia/macrophage efferocytosis and inflammation resolution in stroke mice. , 2019, JCI insight.
[26] K. Saijo,et al. The Endocannabinoid System as a Window Into Microglial Biology and Its Relationship to Autism , 2019, Front. Cell. Neurosci..
[27] Chao Li,et al. CB2 Cannabinoid receptor agonist ameliorates novel object recognition but not spatial memory in transgenic APP/PS1 mice , 2019, Neuroscience Letters.
[28] T. Bisogno,et al. Targeted Lipidomics Investigation of N ‐acylethanolamines in a Transgenic Mouse Model of AD: A Longitudinal Study , 2019, European Journal of Lipid Science and Technology.
[29] Yumin Zhang,et al. Anti-Inflammatory Effects by Pharmacological Inhibition or Knockdown of Fatty Acid Amide Hydrolase in BV2 Microglial Cells , 2019, Cells.
[30] D. Friedman,et al. Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders , 2019, The Lancet Neurology.
[31] Í. Azcoitia,et al. The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia , 2019, Brain, Behavior, and Immunity.
[32] D. Brooks,et al. Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume , 2019, Neurology.
[33] S. Warrier,et al. Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets , 2019, British journal of pharmacology.
[34] B. Cravatt,et al. Role of interleukin 1‐beta in the inflammatory response in a fatty acid amide hydrolase‐knockout mouse model of Alzheimer’s disease , 2018, Biochemical pharmacology.
[35] F. Pavón,et al. Pharmacological blockade of fatty acid amide hydrolase (FAAH) by URB597 improves memory and changes the phenotype of hippocampal microglia despite ethanol exposure , 2018, Biochemical pharmacology.
[36] M. Colonna,et al. The identity and function of microglia in neurodegeneration , 2018, Nature Immunology.
[37] M. Heneka,et al. Cannabinoid 1 Receptor Signaling on Hippocampal GABAergic Neurons Influences Microglial Activity , 2018, Front. Mol. Neurosci..
[38] Taotao Lao,et al. Roles of Microglial and Monocyte Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid-β and Tau Pathologies , 2018, Front. Neurol..
[39] C. Steinhäuser,et al. Plaque‐dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer's disease mouse model , 2018, Glia.
[40] A. Zimmer,et al. Cannabinoid Receptor 2-Deficiency Ameliorates Disease Symptoms in a Mouse Model with Alzheimer's Disease-Like Pathology. , 2018, Journal of Alzheimer's disease : JAD.
[41] M. T. Grande,et al. Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer’s disease , 2018, Journal of neuroinflammation.
[42] J. Gan,et al. The inhibition of CB1 receptor accelerates the onset and development of EAE possibly by regulating microglia/macrophages polarization , 2018, Journal of Neuroimmunology.
[43] D. Mango,et al. Early alteration of distribution and activity of hippocampal type‐1 cannabinoid receptor in Alzheimer's disease‐like mice overexpressing the human mutant amyloid precursor protein , 2018, Pharmacological research.
[44] Alzheimer’s Association. 2018 Alzheimer's disease facts and figures , 2018, Alzheimer's & Dementia.
[45] Valerio Chiurchiù,et al. Bioactive Lipids and Chronic Inflammation: Managing the Fire Within , 2018, Front. Immunol..
[46] Hui Zheng,et al. Practical considerations for choosing a mouse model of Alzheimer’s disease , 2017, Molecular Neurodegeneration.
[47] B. Barres,et al. Microglia and macrophages in brain homeostasis and disease , 2017, Nature Reviews Immunology.
[48] C. Serhan,et al. New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. , 2017, Molecular aspects of medicine.
[49] D. Piomelli,et al. TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice , 2017, Nature Communications.
[50] M. Colonna,et al. Microglia Function in the Central Nervous System During Health and Neurodegeneration. , 2017, Annual review of immunology.
[51] M. Glass,et al. Cannabinoid CB1 and CB2 Receptor Signaling and Bias , 2017, Cannabis and cannabinoid research.
[52] M. Heneka,et al. Danger‐associated molecular patterns in Alzheimer’s disease , 2017, Journal of leukocyte biology.
[53] M. F. Troncoso,et al. Galectin-1 circumvents lysolecithin-induced demyelination through the modulation of microglial polarization/phagocytosis and oligodendroglial differentiation , 2016, Neurobiology of Disease.
[54] F. Maxfield,et al. The endocytic pathway in microglia during health, aging and Alzheimer’s disease , 2016, Ageing Research Reviews.
[55] M. A. Pozo,et al. Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease , 2016, Neuropharmacology.
[56] L. Mestre,et al. Microglia activation states and cannabinoid system: Therapeutic implications. , 2016, Pharmacology & therapeutics.
[57] M. Doverskog,et al. Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer’s Disease , 2016, Journal of Alzheimer's disease : JAD.
[58] T. Bisogno,et al. Type-2 cannabinoid receptors in neurodegeneration. , 2016, Pharmacological research.
[59] K. Rhodes,et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.
[60] F. LaFerla,et al. Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer’s disease , 2016, Neuroscience.
[61] R. Ransohoff. A polarizing question: do M1 and M2 microglia exist? , 2016, Nature Neuroscience.
[62] C. Limatola,et al. Dark microglia: A new phenotype predominantly associated with pathological states , 2016, Glia.
[63] C. McPherson,et al. Microglial M1/M2 polarization and metabolic states , 2016, British journal of pharmacology.
[64] J. Fernández-Ruiz,et al. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[65] E. Mandelkow,et al. Tau in physiology and pathology , 2015, Nature Reviews Neuroscience.
[66] R. Maldonado,et al. The endocannabinoid system in guarding against fear, anxiety and stress , 2015, Nature Reviews Neuroscience.
[67] B. Cravatt,et al. Endocannabinoid regulation of amyloid-induced neuroinflammation , 2015, Neurobiology of Aging.
[68] O. Albayram,et al. Enhanced microglial activity in FAAH(-/-) animals. , 2015, Life sciences.
[69] Ainoa Rueda-Zubiaurre,et al. Endocannabinoids drive the acquisition of an alternative phenotype in microglia , 2015, Brain, Behavior, and Immunity.
[70] D. Otte,et al. Expression Analysis of CB2-GFP BAC Transgenic Mice , 2015, PloS one.
[71] N. Derugin,et al. Lack of the scavenger receptor CD36 alters microglial phenotypes after neonatal stroke , 2015, Journal of neurochemistry.
[72] L. Lue,et al. Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains , 2015, Alzheimer's Research & Therapy.
[73] R. Franco,et al. Alternatively activated microglia and macrophages in the central nervous system , 2015, Progress in Neurobiology.
[74] T. Nakagawa,et al. Activation of mitochondrial transient receptor potential vanilloid 1 channel contributes to microglial migration , 2015, Glia.
[75] Burkhard Becher,et al. Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.
[76] B. Przewłocka,et al. Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures , 2015, Neural plasticity.
[77] D. Holtzman,et al. Three dimensions of the amyloid hypothesis: time, space and 'wingmen' , 2015, Nature Neuroscience.
[78] J. Rinne,et al. Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells , 2015, Journal of Neuroinflammation.
[79] Peter K. Stys,et al. Inefficient clearance of myelin debris by microglia impairs remyelinating processes , 2015, Journal of Experimental Medicine.
[80] O. Garaschuk,et al. Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.
[81] L. Battistini,et al. Endocannabinoid signalling in innate and adaptive immunity , 2015, Immunology.
[82] L. Xiong,et al. Activation of murine microglial N9 cells is attenuated through cannabinoid receptor CB2 signaling. , 2015, Biochemical and biophysical research communications.
[83] A. Pérez-Samartín,et al. Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo , 2015, Glia.
[84] S. Pasquaré,et al. Normal aging in rats and pathological aging in human Alzheimer’s disease decrease FAAH activity: Modulation by cannabinoid agonists , 2014, Experimental Gerontology.
[85] K. Mackie,et al. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies , 2014, Nature Reviews Neuroscience.
[86] M. O’Banion,et al. Are “Resting” Microglia More “M2”? , 2014, Front. Immunol..
[87] R. Franco,et al. The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model , 2014, Neurobiology of Aging.
[88] Mauro Maccarrone,et al. Endocannabinoids, Related Compounds and Their Metabolic Routes , 2014, Molecules.
[89] A. Cuello,et al. Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease , 2014, Neurobiology of Aging.
[90] F. Tchantchou,et al. The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury , 2014, Neuropharmacology.
[91] I. Bechmann,et al. Microglial pathology , 2014, Acta neuropathologica communications.
[92] Teng Jiang,et al. Microglia in Alzheimer's Disease , 2014, BioMed research international.
[93] P. Popovich,et al. Pattern recognition receptors and central nervous system repair , 2014, Experimental Neurology.
[94] M. O’Banion,et al. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed , 2014, Journal of Neuroinflammation.
[95] S. Gordon,et al. The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.
[96] K. Mackie,et al. Parsing the players: 2‐arachidonoylglycerol synthesis and degradation in the CNS , 2014, British journal of pharmacology.
[97] T. Bisogno,et al. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG , 2013, Cell Death and Disease.
[98] J. Delgado-García,et al. Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure. , 2013, The Journal of clinical investigation.
[99] A. Finazzi Agro',et al. Epigenetic mechanisms and endocannabinoid signalling , 2013, The FEBS Journal.
[100] R. Franco,et al. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients , 2013, Neurobiology of Aging.
[101] W. Wong. Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation , 2013, Front. Cell. Neurosci..
[102] G. Feng,et al. Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. , 2012, Cell reports.
[103] K. Blennow,et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.
[104] B. Jin,et al. Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress , 2012, Brain Research Bulletin.
[105] B. Cravatt,et al. DAGLβ Inhibition Perturbs a Lipid Network Involved in Macrophage Inflammatory Responses , 2012, Nature chemical biology.
[106] J. Borrell,et al. CD200‐CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation , 2012, Glia.
[107] F. Moradi,et al. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway , 2012, Neuropharmacology.
[108] D. Nomura,et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. , 2012, Cell reports.
[109] M. Lynch,et al. The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation , 2012, Journal of Neuroinflammation.
[110] Alberto Mantovani,et al. Orchestration of metabolism by macrophages. , 2012, Cell metabolism.
[111] Sean R. Donohue,et al. [125I]SD-7015 reveals fine modalities of CB1 cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer’s disease , 2012, Neurochemistry International.
[112] M. Delgado,et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice , 2012, Journal of Neuroinflammation.
[113] M. Maccarrone,et al. The endocannabinoid system: an overview , 2011, Front. Behav. Neurosci..
[114] D. Nomura,et al. Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation , 2011, Science.
[115] B. Strooper,et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.
[116] Masahiko Watanabe,et al. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. , 2011, Brain : a journal of neurology.
[117] K. Manaye,et al. Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPswe/PS1ΔE9 double transgenic mice , 2011, Brain Research.
[118] T. Hortobágyi,et al. WNT signaling in activated microglia is proinflammatory , 2011, Glia.
[119] S. Nam,et al. Inflammation and Alzheimer’s disease , 2010, Archives of pharmacal research.
[120] N. Stella. Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomas , 2010, Glia.
[121] M. Glass,et al. THEMED ISSUE: CANNABINOIDS REVIEW The endocannabinoid system as a target for the treatment of neurodegenerative disease , 2010 .
[122] R. Pertwee. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. , 2010, Current medicinal chemistry.
[123] M. Citron. Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.
[124] A. Spagnolo,et al. Anandamide enhances IL‐10 production in activated microglia by targeting CB2 receptors: Roles of ERK1/2, JNK, and NF‐κB , 2010, Glia.
[125] N. Stella. Endocannabinoid signaling in microglial cells , 2009, Neuropharmacology.
[126] A. Kluge,et al. Barriers to Organizational Learning: An Integration of Theory and Research , 2009 .
[127] H. Braak,et al. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease , 2009, Acta Neuropathologica.
[128] Z Walker,et al. Microglial activation and amyloid deposition in mild cognitive impairment , 2009, Neurology.
[129] Rebecca M. Sappington,et al. Contribution of TRPV1 to microglia-derived IL-6 and NFkappaB translocation with elevated hydrostatic pressure. , 2008, Investigative ophthalmology & visual science.
[130] B. Cravatt,et al. A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2‐Arachidonoylglycerol , 2007, Chemistry & biology.
[131] J. Whitaker,et al. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators , 2007, FEBS letters.
[132] E. Cudaback,et al. Identification of a Novel Endocannabinoid-Hydrolyzing Enzyme Expressed by Microglial Cells , 2007, The Journal of Neuroscience.
[133] E. Fama,et al. Migration , 2007, Inward Looking.
[134] D. S. Zahm,et al. Lipopolysaccharide and cyclic AMP regulation of CB2 cannabinoid receptor levels in rat brain and mouse RAW 264.7 macrophages , 2006, Journal of Neuroimmunology.
[135] Bill X. Huang,et al. A biosynthetic pathway for anandamide , 2006, Proceedings of the National Academy of Sciences.
[136] P. Anand,et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord , 2006, BMC neurology.
[137] Yun Bai,et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation , 2005, Journal of Neuroinflammation.
[138] Judit K. Makara,et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus , 2005, Nature Neuroscience.
[139] T. Klein. Cannabinoid-based drugs as anti-inflammatory therapeutics , 2005, Nature Reviews Immunology.
[140] M. L. de Ceballos,et al. Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.
[141] E. E. Bagley,et al. Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro , 2004, British journal of pharmacology.
[142] W. Campbell,et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. , 2004, Molecular pharmacology.
[143] Gareth Williams,et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain , 2003, The Journal of cell biology.
[144] M. Maccarrone,et al. The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis , 2003, Cell Death and Differentiation.
[145] K. Mackie,et al. Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.
[146] K. Waku,et al. 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. , 2002, Archives of biochemistry and biophysics.
[147] D. Piomelli,et al. A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.
[148] Stephen P. Mayfield,et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.
[149] M. Herkenham,et al. Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains , 1994, Neuroscience.
[150] H. Higgs,et al. Identification of a phosphatidic acid-preferring phospholipase A1 from bovine brain and testis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[151] L. Horrocks,et al. Neurochemical aspects of Alzheimer's disease: Involvement of membrane phospholipids , 1988, Metabolic Brain Disease.
[152] R. Swerdlow,et al. Effects of Microglial Cytokines on Alzheimer's Disease-Related Phenomena. , 2019, Journal of Alzheimer's disease : JAD.
[153] Liangyu Zhang,et al. Nrf2/ARE pathway inhibits ROS-induced NLRP3 inflammasome activation in BV2 cells after cerebral ischemia reperfusion , 2017, Inflammation Research.
[154] I. Ferrer,et al. 1 CB 1 agonist ACEA protects neurons and reduces the cognitive impairment of AßPP / PS 1 mice , 2015 .
[155] Ester Asoa,et al. 1 CB 2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A PP / PS 1 mice , 2015 .
[156] P. Davies,et al. CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer’s Disease , 2013, Molecular Medicine.
[157] Masahiko Watanabe,et al. Endocannabinoid-mediated control of synaptic transmission. , 2009, Physiological reviews.
[158] Sonja Zehetmayer,et al. Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.
[159] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[160] G. Cabral,et al. Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. , 2001, Advances in experimental medicine and biology.